Fresenius Reaffirms 2026 Outlook

By Public Technologies
  • Fresenius maintained its full-year 2026 outlook.
  • Biopharma revenue is targeted to nearly double by 2030 from 2025, with an EBIT margin of around 20%.
  • The company expects to significantly raise its longer-term Biopharma ambitions following an exclusive development agreement with WuXi Biologics.
  • The agreement provides access to up to 37 biosimilar candidates, potentially expanding the portfolio from 29 to 66 molecules over a decade.
  • Rising development spending will weigh on profitability before products contribute growth; operating cash flow will fund the agreement without additional debt.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2426078_de) on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.